COMPLIANCE INFO_2019 - Laserfiche WebLink

Home Browse Search

8/22/2018 4CARD I REF SAFETY DATA SHEET ISSUED: BK01-C241 Acute Dermal toxicity no data available Skin irritation no data available eye irritation no data available Respiratory or skin sensation no data available Germ cell mutagenicity no data available Carcinogenicity Limited evidence of carcinogenicity in human studies IARC Group 1: Carcinogenic to humans (Quartz) ACGIH No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by ACGIH NTP Known to be human carcinogen (Quartz) OSHA No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by OSHA Reproductive toxicity no data available Specific target organ toxicity - single no data available exposure Specific target organ toxicity - repeated may cause damage to organs through prolonged or repeated exposure exposure - inhalation Aspiration hazard no data available Additional information Prolonged inhalation of crystalline silica may result in silicosis, a disabling pulmonary fibrosis characterized by fibrotic changes and miliary nodules in the lungs, a dry cough, shortness of breath, emphysema, decreased chest expansion, and increased susceptibility to tuberculosis. In advanced stage, loss of appetite, pleuric pain, and total incapacity to work. Advanced silicosis may result in death due to cardiac failure or destruction of lung tissue. Crystalline silica is classified as group 1 "known to be carcinogenic to humans" by IARC and "sufficient evidence" of carcinogenicity by the NTP.,The chronic health risks are associated with respirable particles of 3-4 um over protracted periods of time. Currently, there is a limited understanding of the mechanisms of quartz toxicity, including its mechanisms for lung carcinogenicity. Additional studies are needed to determine whether the cell transforming activity of quartz is related to its carcinogenic potential. Additional information Liver- Irregularities - based on human evidence Diethanolamine 111-42-2 LD50 Oral - Rat- male and female 1,600 mg/kg OECD Test Guideline 401 LD50 Dermal - Rabbit 12,200 m k LD50 Intraperitoneal - Rat 120 mg/kg LD50 Intravenous - Rat 778 mg/kg Skin Corrosion irritation No data available Serious eye damage/eye irritation Rabbit- Risk of serious damage to eyes OECD Test Guideline 405 Respiratory or skin sensitization Guinea pig - Did not cause sensitization on laboratory animals Germ cell mutagenicity Micronucleus test lymphocyte- Result Negative Mutagenicity (micronucleus test) Mouse Result: Negative male and female Carcinogenicity - IARC 2B - Group 2B Possibly carcinogenic to humans Carcinogenicity - NTP No component of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP Carcinogenicity -OSHA No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by OSHA Reproductive toxicity No data available Specific target organ toxicity - single No data available exposure Specific target organ toxicity - repeated No data available exposure Aspiration hazard No data available Additional information Repeated dose toxicity - rat- male and female - oral Lowest observed adverse effect level - 25 mg/kg RTECS: KL297500 Additional information To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated Additional information Liver- Irregularities - Based on Human Evidence Limestone 1317-65-3 Draize test rabbit eye 750 ug/2 H severe Draize test rabbit skin 500 mg/ 4H moderate Oral rat: LD50 6450 m k ACGIH IARC NTP CA Prop 65 Not listed Epidemiology No information available Teratogenicity No information available E Page 6 of 13 I i 6